r.rotation.to⌕ Search stocks, people, sectors
Following this device: dark.
Request a free account

Follow the people · Insider

MM

Masaru Matsuda

Insider · Officer · ARQT

Masaru Matsuda files insider transactions with the SEC as an officer of Arcutis Biotherapeutics. We hold 6 disclosed purchases and sales filed since 12 February 2020, 2 of them in the last 90 days.

  • Files for 2 companiesARQT, HALO
  • Disclosed buys and sells6 in all, 2 in the last 90 days
  • Last disclosure10 September 2026

Positions held

2 posts we hold — a term names its own dates; a run of filings only says when they filed
  • Filed 3 January 2022 — 8 September 2026Officer · Arcutis Biotherapeutics 71 Form 4 lines · source: SEC Form 4
  • Filed 10 February 2020 — 4 September 2021SVP, General Counsel · Halozyme Therapeutics 19 Form 4 lines · source: SEC Form 4

Every transaction

90 transactions from SEC Form 4 — one row each, sort any column, open a row for the filing
90 of 90 shown
8 Sep 202610 Sep 2026SEC Form 42 dsold on the open marketArcutis Biotherapeutics9,989 sharesdown −2.1%up +2.2%
3 Aug 20265 Aug 2026SEC Form 42 dsold on the open marketArcutis Biotherapeutics1,230 sharesdown −7.9%down −11.9%
4 May 20266 May 2026SEC Form 42 dsold on the open marketArcutis Biotherapeutics7,372 sharesup +1.7%down −1.2%
4 May 20266 May 2026SEC Form 42 dsold on the open marketArcutis Biotherapeutics884 sharesup +1.7%down −1.2%
2 Mar 20263 Mar 2026SEC Form 41 dsold on the open marketArcutis Biotherapeutics6,553 sharesdown −3.5%up +1.2%
2 Mar 20263 Mar 2026SEC Form 41 dsold on the open marketArcutis Biotherapeutics193 sharesdown −3.5%up +1.2%
2 Mar 20263 Mar 2026SEC Form 41 dsold on the open marketArcutis Biotherapeutics1,987 sharesdown −3.5%up +1.2%
2 Mar 20263 Mar 2026SEC Form 41 dsold on the open marketArcutis Biotherapeutics6,553 sharesdown −3.5%up +1.2%
2 Mar 20263 Mar 2026SEC Form 41 dsold on the open marketArcutis Biotherapeutics193 sharesdown −3.5%up +1.2%
2 Mar 20263 Mar 2026SEC Form 41 dsold on the open marketArcutis Biotherapeutics1,987 sharesdown −3.5%up +1.2%
27 Feb 20263 Mar 2026SEC Form 44 dwas grantednot a tradeArcutis Biotherapeutics37,000 sharesdown −11.4%up +1.2%
27 Feb 20263 Mar 2026SEC Form 44 dsold on the open marketArcutis Biotherapeutics3,325 sharesdown −11.4%up +1.2%
27 Feb 20263 Mar 2026SEC Form 44 dwas grantednot a tradeArcutis Biotherapeuticsderivative97,000 sharesdown −11.4%up +1.2%
27 Feb 20263 Mar 2026SEC Form 44 dwas grantednot a tradeArcutis Biotherapeuticsderivative97,000 sharesdown −11.4%up +1.2%
27 Feb 20263 Mar 2026SEC Form 44 dwas grantednot a tradeArcutis Biotherapeutics37,000 sharesdown −11.4%up +1.2%
27 Feb 20263 Mar 2026SEC Form 44 dsold on the open marketArcutis Biotherapeutics3,325 sharesdown −11.4%up +1.2%
2 Feb 20264 Feb 2026SEC Form 42 dsold on the open marketArcutis Biotherapeutics7,983 sharesdown −6.6%down −8.4%
2 Feb 20264 Feb 2026SEC Form 42 dsold on the open marketArcutis Biotherapeutics8,562 sharesdown −6.6%down −8.4%
2 Feb 20264 Feb 2026SEC Form 42 dsold on the open marketArcutis Biotherapeutics19,379 sharesdown −6.6%down −8.4%
2 Feb 20264 Feb 2026SEC Form 42 dsold on the open marketArcutis Biotherapeutics4,714 sharesdown −6.6%down −8.4%
2 Feb 20264 Feb 2026SEC Form 42 dsold on the open marketArcutis Biotherapeutics7,983 sharesdown −6.6%down −8.4%
2 Feb 20264 Feb 2026SEC Form 42 dsold on the open marketArcutis Biotherapeutics8,562 sharesdown −6.6%down −8.4%
2 Feb 20264 Feb 2026SEC Form 42 dsold on the open marketArcutis Biotherapeutics19,379 sharesdown −6.6%down −8.4%
2 Feb 20264 Feb 2026SEC Form 42 dsold on the open marketArcutis Biotherapeutics4,714 sharesdown −6.6%down −8.4%
1 Dec 20253 Dec 2025SEC Form 42 dsold on the open marketArcutis Biotherapeutics1,657 sharesdown −21.4%down −20.3%
19 Nov 202521 Nov 2025SEC Form 42 dsold on the open marketArcutis Biotherapeutics989 sharesdown −14.4%down −19.0%
19 Nov 202521 Nov 2025SEC Form 42 dsold on the open marketArcutis Biotherapeutics1,561 sharesdown −14.4%down −19.0%
3 Nov 20255 Nov 2025SEC Form 42 dsold on the open marketArcutis Biotherapeutics7,165 sharesdown −3.5%down −2.0%
3 Nov 20255 Nov 2025SEC Form 42 dsold on the open marketArcutis Biotherapeutics43 sharesdown −3.5%down −2.0%
4 Sep 20258 Sep 2025SEC Form 44 dsold on the open marketArcutis Biotherapeutics36,130 sharesup +47.3%up +37.8%
4 Aug 20255 Aug 2025SEC Form 41 dsold on the open marketArcutis Biotherapeutics6,330 sharesup +64.5%up +55.9%
28 May 202529 May 2025SEC Form 41 dsold on the open marketArcutis Biotherapeutics1,800 sharesup +75.9%up +74.7%
2 May 20255 May 2025SEC Form 43 dsold on the open marketArcutis Biotherapeutics5,030 sharesup +56.7%up +55.0%
3 Mar 20254 Mar 2025SEC Form 41 dsold on the open marketArcutis Biotherapeutics3,263 sharesup +86.2%up +78.2%
28 Feb 20254 Mar 2025SEC Form 44 dwas grantednot a tradeArcutis Biotherapeuticsderivative89,000 sharesup +74.5%up +78.2%
28 Feb 20254 Mar 2025SEC Form 44 dwas grantednot a tradeArcutis Biotherapeutics34,000 sharesup +74.5%up +78.2%
3 Feb 20254 Feb 2025SEC Form 41 dsold on the open marketArcutis Biotherapeutics8,338 sharesup +88.2%up +82.3%
30 Nov 20243 Dec 2024SEC Form 43 dbought on the open marketArcutis Biotherapeutics1,657 sharesup +83.2%up +94.7%
19 Nov 202419 Nov 2024SEC Form 40 dsold on the open marketArcutis Biotherapeutics1,775 sharesup +136.7%up +136.7%
18 Nov 202419 Nov 2024SEC Form 41 dwas grantednot a tradeArcutis Biotherapeutics4,875 sharesup +153.3%up +136.7%
4 Nov 20245 Nov 2024SEC Form 41 dsold on the open marketArcutis Biotherapeutics5,015 sharesup +173.9%up +156.8%
2 Aug 20245 Aug 2024SEC Form 43 dsold on the open marketArcutis Biotherapeutics5,220 sharesup +158.2%up +162.6%
31 May 20243 Dec 2024SEC Form 4186 dbought on the open marketArcutis Biotherapeutics4,000 sharesup +185.7%up +94.7%
28 May 202429 May 2024SEC Form 41 dsold on the open marketArcutis Biotherapeutics1,775 sharesup +169.0%up +178.1%
27 May 202429 May 2024SEC Form 42 dwas grantednot a tradeArcutis Biotherapeutics4,875 sharesup +160.8%up +178.1%
2 May 20243 May 2024SEC Form 41 dsold on the open marketArcutis Biotherapeutics5,016 sharesup +177.7%up +198.6%
4 Mar 20246 Mar 2024SEC Form 42 dsold on the open marketArcutis Biotherapeutics3,760 sharesup +118.1%up +128.8%
13 Feb 202415 Feb 2024SEC Form 42 dreturned to the issuernot a tradeArcutis Biotherapeuticsderivative185,000 sharesup +246.2%up +199.7%
13 Feb 202415 Feb 2024SEC Form 42 dreturned to the issuernot a tradeArcutis Biotherapeuticsderivative35,300 sharesup +246.2%up +199.7%
13 Feb 202415 Feb 2024SEC Form 42 dreturned to the issuernot a tradeArcutis Biotherapeuticsderivative55,800 sharesup +246.2%up +199.7%
13 Feb 202415 Feb 2024SEC Form 42 dwas grantednot a tradeArcutis Biotherapeutics74,000 sharesup +246.2%up +199.7%
13 Feb 202415 Feb 2024SEC Form 42 dwas grantednot a tradeArcutis Biotherapeutics17,650 sharesup +246.2%up +199.7%
13 Feb 202415 Feb 2024SEC Form 42 dwas grantednot a tradeArcutis Biotherapeutics27,900 sharesup +246.2%up +199.7%
12 Jan 202417 Jan 2024SEC Form 45 dwas grantednot a tradeArcutis Biotherapeuticsderivative176,000 sharesup +556.2%up +615.1%
12 Jan 202417 Jan 2024SEC Form 45 dwas grantednot a tradeArcutis Biotherapeutics28,000 sharesup +556.2%up +615.1%
21 Nov 202321 Nov 2023SEC Form 40 dsold on the open marketArcutis Biotherapeutics1,850 sharesup +1163.8%up +1163.8%
18 Nov 202321 Nov 2023SEC Form 43 dwas grantednot a tradeArcutis Biotherapeutics4,875 sharesup +1070.8%up +1163.8%
31 May 20232 Jun 2023SEC Form 42 dsold on the open marketArcutis Biotherapeutics1,830 sharesup +218.0%up +191.3%
31 May 20232 Jun 2023SEC Form 42 dwas grantednot a tradeArcutis Biotherapeutics1,463 sharesup +218.0%up +191.3%
27 May 20232 Jun 2023SEC Form 46 dwas grantednot a tradeArcutis Biotherapeutics4,875 sharesup +184.3%up +191.3%
2 Mar 20236 Mar 2023SEC Form 44 dwas grantednot a tradeArcutis Biotherapeuticsderivative55,800 sharesup +51.0%up +64.3%
2 Mar 20236 Mar 2023SEC Form 44 dsold on the open marketArcutis Biotherapeutics1,416 sharesup +51.0%up +64.3%
2 Mar 20236 Mar 2023SEC Form 44 dsold on the open marketArcutis Biotherapeutics18 sharesup +51.0%up +64.3%
2 Mar 20236 Mar 2023SEC Form 44 dwas grantednot a tradeArcutis Biotherapeutics21,000 sharesup +51.0%up +64.3%
21 Nov 202222 Nov 2022SEC Form 41 dsold on the open marketArcutis Biotherapeutics1,720 sharesup +31.2%up +30.4%
18 Nov 202222 Nov 2022SEC Form 44 dwas grantednot a tradeArcutis Biotherapeutics4,875 sharesup +27.6%up +30.4%
2 Jun 20222 Jun 2022SEC Form 40 dsold on the open marketArcutis Biotherapeutics1,795 sharesup +16.1%up +16.1%
27 May 20222 Jun 2022SEC Form 46 dwas grantednot a tradeArcutis Biotherapeutics4,875 sharesup +13.8%up +16.1%
3 Mar 20227 Mar 2022SEC Form 44 dwas grantednot a tradeArcutis Biotherapeuticsderivative35,300 sharesup +35.2%up +44.7%
3 Mar 20227 Mar 2022SEC Form 44 dwas grantednot a tradeArcutis Biotherapeutics13,300 sharesup +35.2%up +44.7%
3 Jan 20225 Jan 2022SEC Form 42 dwas grantednot a tradeArcutis Biotherapeuticsderivative185,000 sharesup +4.8%up +17.7%
4 Sep 20217 Sep 2021SEC Form 43 dexercised options overnot a tradeHalozyme Therapeuticsderivative6,883 sharesup +153.9%up +149.6%
4 Sep 20217 Sep 2021SEC Form 43 dexercised options overnot a tradeHalozyme Therapeutics6,883 sharesup +153.9%up +149.6%
4 Sep 20217 Sep 2021SEC Form 43 dhad shares withheld for taxnot a tradeHalozyme Therapeutics3,412 sharesup +153.9%up +149.6%
15 Feb 202117 Feb 2021SEC Form 42 dwas grantednot a tradeHalozyme Therapeuticsderivative23,311 sharesup +115.1%up +117.7%
15 Feb 202117 Feb 2021SEC Form 42 dwas grantednot a tradeHalozyme Therapeuticsderivative13,544 sharesup +115.1%up +117.7%
12 Feb 202112 Feb 2021SEC Form 40 dexercised options overnot a tradeHalozyme Therapeutics4,129 sharesup +115.1%up +115.1%
12 Feb 202112 Feb 2021SEC Form 40 dhad shares withheld for taxnot a tradeHalozyme Therapeutics2,047 sharesup +115.1%up +115.1%
12 Feb 202112 Feb 2021SEC Form 40 dexercised options overnot a tradeHalozyme Therapeuticsderivative4,129 sharesup +115.1%up +115.1%
10 Feb 202112 Feb 2021SEC Form 42 dexercised options overnot a tradeHalozyme Therapeutics6,257 sharesup +111.9%up +115.1%
10 Feb 202112 Feb 2021SEC Form 42 dhad shares withheld for taxnot a tradeHalozyme Therapeutics3,203 sharesup +111.9%up +115.1%
10 Feb 202112 Feb 2021SEC Form 42 dexercised options overnot a tradeHalozyme Therapeuticsderivative6,257 sharesup +111.9%up +115.1%
4 Sep 20204 Sep 2020SEC Form 40 dexercised options overnot a tradeHalozyme Therapeuticsderivative6,884 sharesup +287.0%up +287.0%
4 Sep 20204 Sep 2020SEC Form 40 dexercised options overnot a tradeHalozyme Therapeutics6,884 sharesup +287.0%up +287.0%
4 Sep 20204 Sep 2020SEC Form 40 dhad shares withheld for taxnot a tradeHalozyme Therapeutics2,380 sharesup +287.0%up +287.0%
12 Feb 202013 Feb 2020SEC Form 41 dexercised options overnot a tradeHalozyme Therapeuticsderivative4,130 sharesup +436.0%up +428.9%
12 Feb 202013 Feb 2020SEC Form 41 dexercised options overnot a tradeHalozyme Therapeutics4,130 sharesup +436.0%up +428.9%
12 Feb 202013 Feb 2020SEC Form 41 dhad shares withheld for taxnot a tradeHalozyme Therapeutics1,681 sharesup +436.0%up +428.9%
10 Feb 202012 Feb 2020SEC Form 42 dwas grantednot a tradeHalozyme Therapeuticsderivative53,211 sharesup +436.5%up +436.0%
10 Feb 202012 Feb 2020SEC Form 42 dwas grantednot a tradeHalozyme Therapeuticsderivative25,026 sharesup +436.5%up +436.0%

Both percentages are the stock’s move, not Masaru Matsuda’s return: a disclosure gives a band, never an amount, so nobody can say how much was bought or what it made. They run to the last close we hold — 11 Sep 2026, except where a name has since delisted, when the row names its own last session. We publish no close, no volume and no dollar figure behind them. 90 of the 90 rows shown carry a percentage; the rest are dashes with the reason on the row.

Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.

Some filings reach us as photographs of paper rather than as a form we can read as text. Those are shown here only once they have been read and checked, so this page can hold fewer lines than the filings behind it contain. The link on every row opens the original document, which is always the full record.